II 

108TH CONGRESS 

2D SESSION S. 2195

To amend the Controlled Substances Act to clarify the definition of anabolic 

steroids and to provide for research and education activities relating 

to steroids and steroid precursors. 

IN THE SENATE OF THE UNITED STATES 

MARCH 11, 2004

Mr. BIDEN (for himself, Mr. HATCH, Mr. GRASSLEY, Mr. HARKIN, Mr. STEVENS, Mr. MCCAIN, Mr. NELSON of Florida, Mrs. FEINSTEIN, Mr. 

ALLEN, and Ms. MURKOWSKI) introduced the following bill; which was 

read twice and referred to the Committee on the Judiciary 

A BILL

To amend the Controlled Substances Act to clarify the definition of anabolic steroids and to provide for research 

and education activities relating to steroids and steroid 

precursors.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Anabolic Steroid Con5 trol Act of 2004’’. 
2

•S 2195 IS 

1 SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES 

2 ACT. 

3 (a) DEFINITIONS.—Section 102 of the Controlled 

4 Substances Act (21 U.S.C. 802) is amended—

5 (1) in paragraph (41)—

6 (A) by realigning the margin so as to align 

7 with paragraph (40); and 

8 (B) by striking subparagraph (A) and in9 serting the following: 

10 ‘‘(A) The term ‘anabolic steroid’ means any drug or 

11 hormonal substance, chemically and pharmacologically re12 lated to testosterone (other than estrogens, progestins, 

13 corticosteroids, and dehydroepiandrosterone), and in14 cludes—

15 ‘‘(i) androstanediol—

16 ‘‘(I) 3β,17β-dihydroxy-5α-androstane; and 

17 ‘‘(II) 3α,17β-dihydroxy-5α-androstane; 

18 ‘‘(ii) androstanedione (5α-androstan-3,17-

19 dione); 

20 ‘‘(iii) androstenediol—

21 ‘‘(I) 1-androstenediol (3β,17β-dihydroxy22 5α-androst-1-ene); 

23 ‘‘(II) 1-androstenediol (3α,17β-dihydroxy24 5α-androst-1-ene); 

25 ‘‘(III) 4-androstenediol (3β,17β-dihydroxy26 androst-4-ene); and 
3

•S 2195 IS 

1 ‘‘(IV) 5-androstenediol (3β,17β-dihydroxy2 androst-5-ene); 

3 ‘‘(iv) androstenedione—

4 ‘‘(I) 1-androstenedione ([5α]-androst-1-en5 3,17-dione); 

6 ‘‘(II) 4-androstenedione (androst-4-en7 3,17-dione); and 

8 ‘‘(III) 5-androstenedione (androst-5-en9 3,17-dione); 

10 ‘‘(v) bolasterone (7α,17α-dimethyl-17β11 hydroxyandrost-4-en-3-one); 

12 ‘‘(vi) boldenone (17β-hydroxyandrost-1,4,-diene13 3-one); 

14 ‘‘(vii) calusterone (7β,17α-dimethyl-17β15 hydroxyandrost-4-en-3-one); 

16 ‘‘(viii) clostebol (4-chloro-17β-hydroxyandrost-4-

17 en-3-one); 

18 ‘‘(ix) dehydrochloromethyltestosterone (4-

19 chloro-17β-hydroxy-17α-methyl-androst-1,4-dien-3-

20 one); 

21 ‘‘(x) >1-dihydrotestosterone (a.k.a. ‘1-testos22 terone’) (17β-hydroxy-5α-androst-1-en-3-one); 

23 ‘‘(xi) 4-dihydrotestosterone (17β-hydroxy24 androstan-3-one); 
4

•S 2195 IS 

1 ‘‘(xii) drostanolone (17β-hydroxy-2α-methyl-5α2 androstan-3-one); 

3 ‘‘(xiii) ethylestrenol (17α-ethyl-17β-hydroxyestr4 4-ene); 

5 ‘‘(xiv) fluoxymesterone (9-fluoro-17α-methyl6 11β,17β-dihydroxyandrost-4-en-3-one); 

7 ‘‘(xv) formebolone (2-formyl-17α-methyl8 11α,17β-dihydroxyandrost-1,4-dien-3-one); 

9 ‘‘(xvi) furazabol (17α-methyl-17β10 hydroxyandrostano[2,3-c]-furazan); 

11 ‘‘(xvii) 13α-ethyl-17α-hydroxygon-4-en-3-one; 

12 ‘‘(xviii) 4-hydroxytestosterone (4,17β-dihydroxy13 androst-4-en-3-one); 

14 ‘‘(xix) 4-hydroxy-19-nortestosterone (4,17β15 dihydroxy-estr-4-en-3-one); 

16 ‘‘(xx) mestanolone (17α-methyl-17β-hydroxy17 5α-androstan-3-one); 

18 ‘‘(xxi) mesterolone (1α-methyl-17β-hydroxy19 [5α]-androstan-3-one); 

20 ‘‘(xxii) methandienone (17α-methyl-17β21 hydroxyandrost-1,4-dien-3-one); 

22 ‘‘(xxiii) methandriol (17α-methyl-3β,17β23 dihydroxyandrost-5-ene); 

24 ‘‘(xxiv) methenolone (1-methyl-17β-hydroxy-5α25 androst-1-en-3-one); 
5

•S 2195 IS 

1 ‘‘(xxv) methyltestosterone (17α-methyl-17β2 hydroxyandrost-4-en-3-one); 

3 ‘‘(xxvi) mibolerone (7α,17α-dimethyl-17β4 hydroxyestr-4-en-3-one); 

5 ‘‘(xxvii) 17α-methyl->1-dihydrotestosterone 

6 (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one) 

7 (a.k.a. ‘17-α-methyl-1-testosterone’); 

8 ‘‘(xxviii) nandrolone (17β-hydroxyestr-4-en-3-

9 one); 

10 ‘‘(xxix) norandrostenediol—

11 ‘‘(I) 19-nor-4-androstenediol (3β, 17β12 dihydroxyestr-4-ene); 

13 ‘‘(II) 19-nor-4-androstenediol (3α, 17β14 dihydroxyestr-4-ene); 

15 ‘‘(III) 19-nor-5-androstenediol (3β, 17β16 dihydroxyestr-5-ene); and 

17 ‘‘(IV) 19-nor-5-androstenediol (3α, 17β18 dihydroxyestr-5-ene); 

19 ‘‘(xxx) norandrostenedione—

20 ‘‘(I) 19-nor-4-androstenedione (estr-4-en21 3,17-dione); and 

22 ‘‘(II) 19-nor-5-androstenedione (estr-5-en23 3,17-dione; 

24 ‘‘(xxxi) norbolethone (13β,17α-diethyl-17β25 hydroxygon-4-en-3-one); 
6

•S 2195 IS 

1 ‘‘(xxxii) norclostebol (4-chloro-17β-hydroxyestr2 4-en-3-one); 

3 ‘‘(xxxiii) norethandrolone (17α-ethyl-17β4 hydroxyestr-4-en-3-one);

5 ‘‘(xxxiv) oxandrolone (17α-methyl-17β-hydroxy6 2-oxa-[5α]-androstan-3-one);

7 ‘‘(xxxv) oxymesterone (17α-methyl-4,17β8 dihydroxyandrost-4-en-3-one); 

9 ‘‘(xxxvi) oxymetholone (17α-methyl-2-

10 hydroxymethylene-17β-hydroxy-[5α]-androstan-3-

11 one); 

12 ‘‘(xxxvii) stanozolol (17α-methyl-17β-hydroxy13 [5α]-androst-2-eno[3,2-c]-pyrazole); 

14 ‘‘(xxxviii) stenbolone (17β-hydroxy-2-methyl15 [5α]-androst-1-en-3-one); 

16 ‘‘(xxxix) testolactone (13-hydroxy-3-oxo-13,17-

17 secoandrosta-1,4-dien-17-oic acid lactone); 

18 ‘‘(xl) testosterone (17β-hydroxyandrost-4-en-3-

19 one); 

20 ‘‘(xli) tetrahydrogestrinone (13β,17α-diethyl21 17β-hydroxygon-4,9,11-trien-3-one); 

22 ‘‘(xlii) trenbolone (17β-hydroxyestr-4,9,11-trien23 3-one); and 

24 ‘‘(xliii) any salt, ester, or ether of a drug or 

25 substance described in this paragraph.’’; and 
7

•S 2195 IS 

1 (2) in paragraph (44), by inserting ‘‘anabolic 

2 steroids,’’ after ‘‘marihuana,’’. 

3 (b) AUTHORITY AND CRITERIA FOR CLASSIFICA4 TION.—Section 201(g) of the Controlled Substances Act 

5 (21 U.S.C. 811(g)) is amended—

6 (1) in paragraph (1), by striking ‘‘substance 

7 from a schedule if such substance’’ and inserting 

8 ‘‘drug which contains a controlled substance from 

9 the application of titles II and III of the Comprehen10 sive Drug Abuse Prevention and Control Act (21 

11 U.S.C. 802 et seq.) if such drug’’; and 

12 (2) in paragraph (3), by adding at the end the 

13 following: 

14 ‘‘(C) Upon the recommendation of the Sec15 retary of Health and Human Services, a compound, 

16 mixture, or preparation which contains any anabolic 

17 steroid, which is intended for administration to a 

18 human being or an animal, and which, because of its 

19 concentration, preparation, formulation or delivery 

20 system, does not present any significant potential for 

21 abuse.’’. 

22 (c) ANABOLIC STEROIDS CONTROL ACT.—Section 

23 1903 of the Anabolic Steroids Control Act of 1990 (Public 

24 Law 101–647) is amended—

25 (1) by striking subsection (a); and 
8

•S 2195 IS 

1 (2) by redesignating subsections (b) and (c) as 

2 subsections (a) and (b), respectively. 

3 SEC. 3. SENTENCING COMMISSION GUIDELINES. 

4 The United States Sentencing Commission shall—

5 (1) review the Federal sentencing guidelines 

6 with respect to offenses involving anabolic steroids; 

7 (2) consider amending the Federal sentencing 

8 guidelines to provide for increased penalties with re9 spect to offenses involving anabolic steroids in a 

10 manner that reflects the seriousness of such offenses 

11 and the need to deter anabolic steroid trafficking 

12 and use; and 

13 (3) take such other action that the Commission 

14 considers necessary to carry out this section. 

15 SEC. 4. PREVENTION AND EDUCATION PROGRAMS. 

16 (a) IN GENERAL.—The Secretary of Health and 

17 Human Services (referred to in this Act as the ‘‘Sec18 retary’’) shall award grants to public and nonprofit private 

19 entities to enable such entities to carry out science-based 

20 education programs in elementary and secondary schools 

21 to highlight the harmful effects of anabolic steroids. 

22 (b) ELIGIBILITY.—

23 (1) APPLICATION.—To be eligible for grants 

24 under subsection (a), an entity shall prepare and 

25 submit to the Secretary an application at such time, 
9

•S 2195 IS 

1 in such manner, and containing such information as 

2 the Secretary may require. 

3 (2) PREFERENCE.—In awarding grants under 

4 subsection (a), the Secretary shall give preference to 

5 applicants that intend to use grant funds to carry 

6 out programs based on—

7 (A) the Athletes Training and Learning to 

8 Avoid Steroids program; 

9 (B) the Athletes Targeting Healthy Exer10 cise and Nutrition Alternatives program; and 

11 (C) other programs determined to be effec12 tive by the National Institute on Drug Abuse. 

13 (c) USE OF FUNDS.—Amounts received under a 

14 grant under subsection (a) shall be used primarily for edu15 cation programs that will directly communicate with 

16 teachers, principals, coaches, as well as elementary and 

17 secondary school children concerning the harmful effects 

18 of anabolic steroids. 

19 (d) AUTHORIZATION OF APPROPRIATIONS.—There is 

20 authorized to be appropriated to carry out this section, 

21 $15,000,000 for each of fiscal years 2005 through 2010. 

22 SEC. 5. NATIONAL SURVEY ON DRUG USE AND HEALTH. 

23 (a) IN GENERAL.—The Secretary of Health and 

24 Human Services shall ensure that the National Survey on 
10

•S 2195 IS 

1 Drug Use and Health includes questions concerning the 

2 use of anabolic steroids. 

3 (b) AUTHORIZATION OF APPROPRIATIONS.—There is 

4 authorized to be appropriated to carry out this section, 

5 $1,000,000 for each of fiscal years 2005 through 2010.

Æ